Evidence map›Paper›PMID 26600797›Full record

ReviewInterventional neurology2015

The Latest Information on Intracranial Atherosclerosis: Diagnosis and Treatment.

Jaseong Koo

2 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Interventional neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03507374 early_phase1terminatedstarted 2018, after this paper: background citation

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

Ran2018Enrolled20Registered outcomes5Posted comparisons0ConditionsIntracranial Atherosclerosis, Intraplaque Hemorrhage, StrokeArmsAlirocumab, Placebo
Open the trial in the graph
NCT05907629 recruitingnot on this mapstarted 2024, after this paper: background citation

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

TypeobservationalSponsorYale UniversityRan2024 to 2029Enrolled300ConditionsStroke, Intracranial Atherosclerotic Stenosis (ICAS)ArmsMRI
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Clinical implications of vessel wall imaging-State-of-the-art review.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jaseong KooDepartment of Neurology, Stroke Center at Cardio-Cerebro-Vascular Center, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea.
The Catholic University of Korea Seoul St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intracranial atherosclerotic stenosis (ICAS) is the most common cause of ischemic stroke in the world. ICAS is especially common in the Asian population accounting for 30-50% of all ischemic strokes. The risk of recurrent stroke in patients with symptomatic ICAS is the highest among the stroke subtypes. Two major factors associated with recurrent stroke are high degree (>70%) of stenosis and progression of ICAS. Transcranial Doppler ultrasound, CT angiography, MR angiography, and conventional catheter angiography are used for the diagnosis of ICAS. Today, high-resolution MRI can provide important information to improve the understanding of pathophysiology and diagnosis of ICAS. For prevention of recurrent stroke in patients with ICAS, surgery and endovascular intervention failed to show benefit over best medical treatment. Best medical treatment includes intensive risk factor control and antiplatelet therapy. Various antiplatelet drugs or their combination can be used for prevention of recurrent stroke in patients with ICAS. Cilostazol with or without aspirin is effective in preventing progression of symptomatic ICAS. Cilostazol is also safer than aspirin in terms of bleeding complications.

Indexed as

Intracranial atherosclerosisIschemic strokeTreatment

Identifiers

PMID26600797
PMCPMC4640091
OpenAlexW2155258442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.